Format

Send to

Choose Destination
See comment in PubMed Commons below
World J Gastroenterol. 2012 Jun 21;18(23):2895-901. doi: 10.3748/wjg.v18.i23.2895.

Potential prospects of nanomedicine for targeted therapeutics in inflammatory bowel diseases.

Abstract

Inflammatory bowel diseases (IBDs) such as Crohn's disease are highly debilitating. There are inconsistencies in response to and side effects in the current conventional medications, failures in adequate drug delivery, and the lack of therapeutics to offer complete remission in the presently available treatments of IBD. This suggests the need to explore beyond the horizons of conventional approaches in IBD therapeutics. This review examines the arena of the evolving IBD nanomedicine, studied so far in animal and in vitro models, before comprehensive clinical testing in humans. The investigations carried out so far in IBD models have provided substantial evidence of the nanotherapeutic approach as having the potential to overcome some of the current drawbacks to conventional IBD therapy. We analyze the pros and cons of nanotechnology in IBD therapies studied in different models, aimed at different targets and mechanisms of IBD pathogenesis, in an attempt to predict its possible impact in humans.

KEYWORDS:

Crohn’s disease; Inflammatory bowel disease; Nanomedicine; Tumor necrosis factor-α; Ulcerative colitis

PMID:
22736912
PMCID:
PMC3380316
DOI:
10.3748/wjg.v18.i23.2895
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Baishideng Publishing Group Inc. Icon for PubMed Central
    Loading ...
    Support Center